Partnership website: https://dutpartnership.eu/
The Driving Urban Transitions is an co-funded partnership, bringing together private and public stakeholders in the research and innovation ecosystems. The DUT partnership incorporates all urban stakeholders (local authorities, municipalities, business and citizens) to co-create innovative, systemic and people-centric approaches, tools, methods and services in support of urban transformative transitions.
CET Partnership aims to achieve this through annual calls addressing three transition pathways, further divided in three themes:
There are two active Flemish participating members in the DUT call: Flanders Innovation & Entrepreneurship (VLAIO) and the Fund for Scientific Research (FWO). The latest DUT call for Flemish participants is open until 21 November 2023.
VLAIO
For consortia applying through VLAIO, more information can be found on the official webpage. Applications can include a research project, a development project or a PILBO application.
VLAIO has a total budget commitment of €800.000. A project can attain a maximum funding of €500.000.
PILBO has various requirements and funding characteristics:
It is highly advised to contact VLAIO to ensure project funding eligibility (see contact details below).
FWO
For consortia applying through FWO, more information can be found on the official webpage. Applications can include fundamental research ("FO") and strategic basic research ("SBO").
FWO will support at least three Flemish projects with a maximum funding support of €250.000. A project can run for a maximum of 36 months.
A project coordinator can only apply for one DUT project as coordinator. Project applicants can only join a maximum of two different DUT projects/consortia.
It is highly advised to contact FWO to ensure project funding eligibility (see contact details below).
The DUT Partnership has a matchmaking platform for interested parties to connect and collaborate.
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.